10-12 October, 2017
Frankfurt, Germany

Speakers

Expand/Collapse

Claus Kremoser
Chief Executive Officer
Phenex

Dr Claus Kremoser is the Chief Executive Officer of Phenex Pharmaceuticals AG. Phenex is a drug discovery company that focuses on the identification and early development of small molecule drugs that target novel receptors. Claus is also a Member of the Board for Avelas Biosciences and is involved with BIO Deutschland and BioRN Network. Prior to this Claus has held positions of responsibility at LION Bioscience and Ernst & Young. Claus received his PhD in Molecular Developmental Neurobiology from Max-Plank Institute.

Day One

Wednesday 11th October, 2017

14:00 | Truthful In-Depth Review of the Advantages & Disadvantages of Preclinical Models

Dean Hum
Chief Scientific Officer
Genfit

Dean Hum earned a Ph.D. in Biochemistry from McGill University in Montreal in 1990. An expert in the modulation of transcription factors and nuclear receptors associated with endocrine and cardiometabolic diseases, he held a research position at the University of California in San Francisco before becoming a Professor at Laval University in Quebec. He joined GENFIT in 2000 as Chief Scientific Officer. Dean Hum is today a key person in the organization of GENFIT. In particular, he is responsible for defining, implementing, employing and coordinating short-, medium- and long-term strategies relating to R&D programs and portfolio. He coordinates all R&D activities with the CEO and in close collaboration with scientific officers and project managers.

Day Two

Thursday 12th October, 2017

09:30 | Identification of Biomarkers for the Diagnosis of NASH

Jonathan Roth
Senior Director, In Vivo Pharmacology
Intercept Pharmaceuticals

Jonathan D. Roth, PhD has worked on metabolic diseases for >15 years within the biotech industry and has held positions of increasing responsibility at Amylin, Janssen and Intercept Pharmaceuticals. Dr. Roth has helped develop and optimize translational models of diet induced obesity, diabetes and more recently a diet-induced and biopsy-confirmed NASH. He is currently the Sr. Director of In Vivo Pharmacology at Intercept.

Day One

Wednesday 11th October, 2017

15:45 | Preclinical Model & Methods Optimization: Lessons from Developing 2nd Generation FXR Agonists for NASH

Pierre Broqua
Chief Scientific Officer
Inventiva

Dr Broqua brings over 25 years of experience in drug discovery and innovative research to Inventiva. Before co-founding Inventiva, he successfully managed numerous research programs leading to the discovery of highly innovative preclinical and clinical compounds, in particular during his tenure at Ferring Pharmaceuticals from 1997 to 2002 and Fournier Laboratories from 2002 to 2005, as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010 and finally as Head of Research for the Abbott Dijon R&D site. One of his most notable achievements was his co-discovery, while head of Pharmacology at Ferring Pharmaceuticals, of the GnRH antagonist Degarelix (now marketed under the brand name Firmagon®). Dr Broqua holds a Ph.D in Pharmacology from the University of Paris Descartes and has a master’s degree in Chemistry and Biochemistry from Université Pierre et Marie Curie, Paris.

Day Two

Thursday 12th October, 2017

15:00 | IVA337: Effectively Targeting NASH

Zhibo Gai
Post Doc
University Hospital of Zurich

Zhibo Gai did his PhD in Molecular Pathology at Wakayama Medical University, Japan.  He joined the research group of Prof. Kullak at the Department of Clinical Pharmacology and Toxicology, University Hospital Zurich in 2011.  He established different mouse kidney disease models and examined FXR function in the kidney.  The main research field is about obesity-related kidney injury and lipid metabolism.

Day Two

Thursday 12th October, 2017

12:00 | Determine Protective Effects of FXR Agonists on Kidney Function in Obesity

Hans Schambye
Chief Executive officer
Galecto Biotech

Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Previously, Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009, Chairman of Forward Pharma (Nasdaq: FWP) from 2005-2010 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

Day One

Wednesday 11th October, 2017

13:30 | Analyse Recent Progress in Targeting NASH Fibrosis - Novel Inhibitors of Galectin-3

James Trevaskis
Principal Scientist & Head of In Vivo Pharmacology
MedImmune

James is an experienced scientist with strong in vivo pharmacology background, with emphasis on identification and validation of novel targets for the potential treatment of metabolic diseases, particularly obesity, diabetes and NASH. He has significant experience in leveraging combination strategies for the treatment of metabolic diseases. He has led target discovery and validation, and drug development project teams throughout his 10 years in industry, including nomination of clinical development candidates.

Day Two

Thursday 12th October, 2017

11:30 | Prosecuting Metabolic Modulators as NASH Therapeutics

Marie Wickström Lindholm
Expert Scientist
Roche Innovation Center Copenhagen

Marie is an Expert Scientist within the Discovery Technology division at Roche Innovation Center Copenhagen. Prior to this Marie held positions of responsibility and was the Director is Discovery Biology at Santaris, which was acquired by Roche. Marie was also an Assistant/Associate Professor at Lund University in Experimental Cardiovascular Research, in the group of Pr. Jan Nilsson. In 1995, Marie received her PhD in Medicinal Chemistry from the Uppsala University.

Day One

Wednesday 11th October, 2017

11:30 | Exploring Key Regulators in NASH

Matthias Ocker
Head, Biomarker Oncology
Bayer

Matthias Ocker studied medicine at the University of Erlangen, Germany, where he obtained his medical doctorate degree in 2000. He got his academic training at the Department of Cellular and Molecular Physiology and the the Department of Gastroenterology of the University Hospital Erlangen. He became Assistant Professor for Experimental Medicine and head of research at the Department of Gastroenterology in Erlangen and was appointed full professor of Medicine and Director of the Institute for Surgical Research at the University of Marburg in 2009. His academic research focused on liver and GI diseases, esp. HCC and the cellular and molecular biology of cell death and epigenetic regulators. He joined Bayer as Director of Experimental Medicine Oncology in Berlin in 2012 and was appointed as VP and Head of Oncology Biomarker Strategists in 2016. He is adjunct professor of Experimental Medicine at the Charité University Hospital Berlin and has authored more than 100 scientific publications.

Day One

Wednesday 11th October, 2017

09:30 | Key Opinion Leaders Discuss: Challenges & Opportunities in NASH Drug Development

Peter Traber
Chief Executive Officer & Chief Medical Officer
Galectin Therapeutics

Dr. Traber is president emeritus of Baylor College of Medicine, where he was chief executive officer from 2003 to 2008. From 2000 to 2003, he was senior vice president of clinical development and medical affairs and chief medical officer of GlaxoSmithKline plc. Dr. Traber served as chief executive officer of the University of Pennsylvania Health System and was chair of the Department of Internal Medicine and chief of gastroenterology for the University of Pennsylvania School of Medicine. Dr. Traber has also managed a molecular biology research laboratory and published over 100 articles of original research, reviews and book chapters. Dr. Traber received his M.D. from Wayne State School of Medicine, a B.S. in chemical engineering from the University of Michigan, and a certificate in medical leadership from Wharton Business School.

Day One

Wednesday 11th October, 2017

16:15 | Chair’s Closing Remarks

08:45 | Chair's Opening Remarks

Day Two

Thursday 12th October, 2017

16:30 | Chair’s Closing Remarks

09:15 | Chair’s Opening Remarks

Philippe Weisel
Chief Medical Officer & Vice President
Genkyotex

Philippe joined Genkyotex in 2010 and is responsible for all clinical development activities.  Previously, Philippe founded Genexion, a clinical development company focused on developing early stage clinical assets with emerging biotech companies and European venture capital firms. Prior to founding Genexion, Philippe was Medical Director at Serono's Swiss and US offices, where he was involved with the global development of several biologics and small molecules. In particular, he led the late-stage clinical development of Raptiva, achieving the first marketing authorization in Europe for a biological therapy targeting psoriasis. Philippe also led the development of Onercept in psoriasis and managed clinical development programs for beta interferon, interleukin-18 binding protein, and atacicept. Prior to joining the biotech industry, he conducted basic research for over five years in the laboratories of Professor Edgar Haber at Harvard Medical School, and Professor Hans Brunner at the Division of Hypertension in Lausanne. Philippe holds a MD degree from the University of Lausanne.

Day One

Wednesday 11th October, 2017

12:00 | Targeting Multiple Fibrogenic Pathways with the NOX1/4 Inhibitor GKT831

Pnina Fishman
Chief Executive Officer & Chief Scientific Officer
Can-fite BioPharma

Prof. Fishman is the scientific founder and CEO of Can-Fite BioPharma and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center. Prof. Fishman is a very accomplished scientist and has authored or co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her past managerial experience included seven years as CEO of Mor Research Application (MRA), the technology transfer arm of Clalit Health Services, the largest healthcare provider in Israel, and the first clinical CRO in Israel. She was also involved in the establishment and served on the Board of Directors of several life sciences technology start-ups.

Day Two

Thursday 12th October, 2017

14:30 | The Anti-Fibrogenic and Liver Protective Effects of Namodenoson (CF102): From Preclinical to Human Studies

Sophie Mégnien
Chief Medical Officer
Genfit

After studying in several countries, including the United States, Sophie Mégnien obtained her degree in Medicine from the University of Paris VI. She is an expert in the clinical development of cardiometabolic diseases (hypercholesterolemia, diabetes) and their vascular (atherosclerosis) and hepatic complications. She completed her internship in the field of clinical trial monitoring. Since then, she has held a number of posts as Project Manager in the R&D departments of various international pharmaceutical companies such as Smithkline Beecham, Glaxo Wellcome and Bayer. After ten years as a Project Manager, Sophie Mégnien became a consultant in Quality Management and Procedures at Sunnikan Consulting before joining Naturalpha, a company specializing in the coordination of clinical projects in the cardiovascular, metabolic and nutrition fields. Sophie Mégnien is currently Chief Medical Officer at GENFIT.

Day One

Wednesday 11th October, 2017

09:00 | Keynote: How is the Field Conquering this Global Health Crisis? Review Latest Advancements in NASH Drug Development

Matthew Coghlan
Senior Director
Matthew Coghlan

Matthew has 20 years of experience in cardiovascular and metabolic disease R&D at SmithKline Beecham and AstraZeneca. During this period Matthew led both small and large molecule projects to candidate nomination. Additionally, Matthew was responsible for building the first biologics portfolio for the AstraZeneca cardio-metabolic therapy area. Between 2013 and 2017 Matthew recruited and led the metabolic disease research group at MedImmune.  Recently Matthew moved to Novo Nordisk where he is responsible for leading the external sourcing of opportunities in NASH, obesity and CKD.

Day One

Wednesday 11th October, 2017

09:30 | Key Opinion Leaders Discuss: Challenges & Opportunities in NASH Drug Development

George O’Rourke
Managing Director
GO Biotech Consulting

George is the Managing Director of GO Biotech Consulting. GO Biotech Consulting is focused on aiding companies with their entry strategies on the European market. Whether this concerns better understanding Named Patient Sales prior to obtaining the MA or identifying Key Opinion Leaders / Institutions or setting-up an "affiliate-less" commercial operations or providing interim management solution. To find out more visit www.gobiotechconsulting.com

Alice E Chen
Associate Director, R&D, Tissue Applications
Organovo

Alice received her PhD in Biology, with an emphasis on Developmental Biology from Johns Hopkins University, in association with the Carnegie Institution of Washington, Department of Embryology and completed a postdoctoral fellowship at the Harvard Stem Cell Institute. Dr. Chen joined Organovo to lead development of in vitro human tissue models in liver and kidney for toxicology research and disease modeling.

Day One

Wednesday 11th October, 2017

15:30 | Modeling Progressive Liver Disease Using 3D Bioprinted Human Liver Tissue

Lars Johansson
Chief Scientific Officer
Antaros Medical

Lars has a background as an Associate Professor in Translational Imaging at Uppsala University, Sweden. He has led a large number of international multi-center imaging trials, and has been PI and co-PI on international grants from EU, JDRF, NIH and EFSD. He has more than 130 peer-reviewed publications in the cardiovascular and metabolism field, with a primary focus on imaging, and more than 20 years’ experience of the medical and pharma Industries. He is currently the CSO at Antaros Medical, a company specialised in decision enabling studies in Cardiovascular and Metabolism drug development. Prior to that he was 10 years at AstraZeneca as Senior Principal Scientist, a role in which he was leading imaging projects ranging from pre-clinical to life cycle management. He has also led several collaborations between industry and academia.

Day Two

Thursday 12th October, 2017

10:00 | The Importance of High Precision Imaging Biomarkers in NASH Drug Development